Title:Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Volume: 27
Issue: 45
Author(s): Shubham Semwal, Rabah Boukherroub, Savvas N. Savvides and Julie Bouckaert*
Affiliation:
- Unite de Glycobiologie Structurale et Fonctionnelle, UMR 8576 from the CNRS and the University of Lille, 50 Avenue Halley, 59650 Villeneuve d'Ascq,France
Keywords:
IgM, glioblastoma, natural antibodies, immunotherapy, microglia, ALK.
Abstract:
Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of
18 months after initial diagnosis and no standard treatment protocol is available. Therefore, there is a need to
search for novel approaches to target glioblastoma.
Objectives: This review intends to capture the role of immunoglobulin-M in cancer, more specifically in
glioblastoma multiforme (GBM), and to compile the latest developments and immunological pathways relevant
to glioblastoma.
Methods: Information on glioblastoma, cancer microenvironment, cancer therapeutics, and how to improve the
scenario were obtained from scientific literature databases such as Pubmed, Medline, Google Scholar, Science
Direct, Springer, Wiley online library, and some data was harvested from regulatory and compliance databases
such as clinicaltrials.gov, FDA database, and WHO Globocan.
Results and Conclusion: Currently, only a limited number of therapies are approved for GBM, and no standard
care is in place in case of disease relapse, necessitating a possible broader perspective in looking at the disease
and its underlying mechanisms.
